NCT00669864View on ClinicalTrials.gov

Effect of Biphasic Insulin Aspart 30 Combined With Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

PHASE4CompletedINTERVENTIONAL
Enrollment

293

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

biphasic insulin aspart 30

Subcutaneous (under the skin) injection, twice daily

DRUG

metformin

Tablets, 1000 - 2000 mg daily

Trial Locations (1)

100034

Beijing

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT00669864 - Effect of Biphasic Insulin Aspart 30 Combined With Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin | Biotech Hunter | Biotech Hunter